HUTCHMED (China) Limited Stock Nasdaq

Equities

HCM

US44842L1035

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
18.53 USD -1.70% Intraday chart for HUTCHMED (China) Limited -1.07% +2.32%
Sales 2024 * 691M Sales 2025 * 849M Capitalization 3.2B
Net income 2024 * -105M Net income 2025 * - EV / Sales 2024 * 4.27 x
Net cash position 2024 * 256M Net cash position 2025 * 383M EV / Sales 2025 * 3.32 x
P/E ratio 2024 *
-29.6 x
P/E ratio 2025 *
269 x
Employees 1,988
Yield 2024 *
-
Yield 2025 *
-
Free-Float 52.39%
More Fundamentals * Assessed data
Dynamic Chart
HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology CI
Hutchmed (China) Chairman Resigns, Successor Named MT
Hutchmed China Simon To leaves role, succeeded by Dan Eldar AN
Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor MT
HUTCHMED Limited Announces Executive Changes CI
Hutchmed (China) to Present Sovleplenib Phase III Data at EHA2024 Congress MT
HUTCHMED Limited Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to Be Presented at the Upcoming EHA2024 Congress CI
Transcript : HUTCHMED Limited Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM
Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies AN
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer MT
HUTCHMED Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China CI
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3% MT
Hutchmed Begins Phase 3 Trials for Leukemia Medication in China MT
HUTCHMED Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui CI
HUTCHMED Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024 CI
More news
1 day-1.70%
1 week-1.07%
1 month+0.11%
3 months+22.63%
6 months-3.89%
Current year+2.32%
More quotes
1 week
18.31
Extreme 18.31
19.23
1 month
18.00
Extreme 18
21.92
Current year
11.93
Extreme 11.9343
21.92
1 year
10.68
Extreme 10.68
21.92
3 years
7.39
Extreme 7.39
43.94
5 years
7.39
Extreme 7.39
43.94
10 years
7.39
Extreme 7.39
43.94
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 04-12-31
Director of Finance/CFO 57 08-06-30
Chief Tech/Sci/R&D Officer 59 21-12-31
Members of the board TitleAgeSince
Director/Board Member 73 17-02-28
Chairman 70 16-07-31
Director/Board Member 71 99-12-31
More insiders
Date Price Change Volume
24-05-31 18.53 -1.70% 62,515
24-05-30 18.85 +1.02% 47,424
24-05-29 18.66 -2.56% 43,714
24-05-28 19.15 +2.24% 198,861
24-05-24 18.73 +0.05% 92,595

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.754 USD
Average target price
5.709 USD
Spread / Average Target
+52.09%
Consensus

Quarterly revenue - Rate of surprise